Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.46 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TPH1 | P17752 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879510 | 0.85 | ABL1 (0.48) | ABL1BCRBMPR1BACVR1BTGFBR1 | |
| SCHEMBL29663821 | 0.85 | ABL1 (0.48) | ABL1BCRBMPR1BACVR1BTGFBR1 | |
| SCHEMBL660025 | 0.85 | ABL1 (0.48) | ABL1BCRBMPR1BACVR1BTGFBR1 | |
| SCHEMBL956866 | 0.81 | FGFR1 (0.56) | ABL1FGFR1FGFR4MAPTTP53 | |
| SCHEMBL19730198 | 0.81 | FGFR1 (0.49) | FGFR1FGFR4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5460397 | 0.81 | ABL1 (0.57) | ABL1BCRFGFR1FGFR4BMPR1B | |
| SCHEMBL2038788 | 0.78 | FGFR1 (0.39) | FGFR1FGFR4KDM4EALDH1A1 | |
| SCHEMBL31240654 | 0.78 | FGFR1 (0.39) | FGFR1FGFR4KDM4EALDH1A1 | |
| SCHEMBL20774516 | 0.78 | HPGD (0.54) | ALDH1A1 | |
| SCHEMBL30552245 | 0.78 | HPGD (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| WO-2015103355-A1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | ABL1 1120/4885BCR 876/4885FGFR1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.